An open, parallel-group, randomised, multi-centre phase IIIstudy to compare the long-term (52-week) safety of Symbicort(budesonide/ formoterol) pMDI 160/4.5 mcg 2 actuations b.i.d. withthat of Symbicort Turbuhaler 160/4.5 mcg 2 inhalations b.i.d. inadults and adolescents with asthma

Study identifier:SD-039-0715

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

An open, parallel-group, randomised, multi-centre phase IIIstudy to compare the long-term (52-week) safety of Symbicort(budesonide/ formoterol) pMDI 160/4.5 mcg 2 actuations b.i.d. withthat of Symbicort Turbuhaler 160/4.5 mcg 2 inhalations b.i.d. inadults and adolescents with asthma

Medical condition

asthma

Phase

Phase 3

Healthy volunteers

-

Study drug

-

Sex

-

Actual Enrollment

-

Study type

Interventional

Age

-

Date

Study Start Date: 01 Mar 2002
Primary Completion Date: -
Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria